The purpose of this study is to find out what effects (good and bad) a combination of cytoxan, epirubicin, and capecitabine have on women with Stage II/II/IIIA breast cancer.
* Each treatment cycle lasts 21 days and patients will participate in a least 4 cycles, but no more than 6 cycles of treatment. * Patients will receive cytoxan (cyclophosphamide) and epirubicin intravenously on day 1 of each treatment cycle. On days 4-17 of each cycle, patients will take capecitabine orally twice a day. * While on the study patients will be required to complete a diary of they capecitabine treatment. * Blood tests will be performed each week along with surveys at the beginning of the trial and certain follow-up visits to evaluate the patient's experience with the oral chemotherapy. * Patients will be on the treatment for 12-18 weeks depending upon whether or not the disease progresses or the patient develops inacceptable side effects.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
55
Intravenously on day 1 of each 21-day treatment cycle for 12-18 weeks depending upon response.
Intravenously on day 1 of each 21-day treatment cycle for 12-18 weeks depending upon response.
Given orally on days 4-17 of each 21-day treatment cycle for 12-18 weeks depending upon response.
Massachusetts General Hospital
Boston, Massachusetts, United States
Dana-Farber Cancer Center
Boston, Massachusetts, United States
To determine the feasibility of administering cytoxan, epirubicin, and capecitabine to women with Stage I/II/IIIA breast cancer.
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.